Ultimate Clinical Outcomes of Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential.

Abstract

The clinical outcome of appendiceal mucinous neoplasm (AMN) is not well understood. This study aimed to compare the long-term outcome for the uncertain malignant potential (UMP) subtype of AMNs with those of the mucinous adenoma (MA) and mucinous adenocarcinoma (MAC) subtypes. In this study, AMNs were classified into three groups (MA, UMP, and MAC), and clinical characteristics, overall survival (OS), and progression-free survival (PFS) were compared among the three groups. The study included 65 AMN patients (26 MA, 20 UMP, and 19 MAC patients). The median follow-up period was 87months (range 0.3-311.0) months. The symptoms at diagnosis and the presence of pseudomyxoma peritonei were more common in the MAC group than in the MA group (P=0.012) or the UMP group (P<0.001). The 5-year OS rates were 95.5% for the MA group, 93.8% for the UMP group, and 78.3% for the MAC group (P<0.001), and the 5-year PFS rates were 95.2% for the MA group, 95% for the UMP group, and 36.8% for the MAC group (P<0.001). Thus, OS and PFS did not differ significantly in the MA and UMP groups (P=0.884 and 0.345, respectively). In contrast, the OS and PFS of the MAC group were worse than in the MA group (P=0.017 and <0.001, respectively) or the UMP group (P<0.001 and 0.001, respectively). The long-term outcome for UMP tumors is similar to that for MA tumors and significantly better than for MAC tumors.